Floatz logo

Sasanlimab

Urologic Neoplasms

NiKang Therapeutics, Inc.monoclonal_antibodyPhase 2Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Urologic Neoplasms cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Region Skane
Phase 4BB
Docetaxel
Sandy Srinivas
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Astellas Pharma Global Development, Inc.
Phase 2BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Eli Lilly and Company
Phase 3B
VOLITINIB
AstraZeneca
Phase 3B

View all 50 →

Same molecule, other indications

Sasanlimab is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
renal cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →